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Although it was originally believed that thyroid hormones
enter target cells by passive diffusion, it is now clear that
cellular uptake is effected by carrier-mediated processes. Two
stereospecific binding sites for each T4 and T3 have been de-
tected in cell membranes and on intact cells from humans and
other species. The apparent Michaelis-Menten values of the
high-affinity, low-capacity binding sites for T4 and T3 are in
the nanomolar range, whereas the apparent Michaelis-
Menten values of the low-affinity, high-capacity binding sites
are usually in the lower micromolar range. Cellular uptake of
T4 and T3 by the high-affinity sites is energy, temperature, and
often Na dependent and represents the translocation of thy-
roid hormone over the plasma membrane. Uptake by the low-
affinity sites is not dependent on energy, temperature, and
Na and represents binding of thyroid hormone to proteins
associated with the plasma membrane. In rat erythrocytes
and hepatocytes, T3 plasma membrane carriers have been ten-
tatively identified as proteins with apparent molecular
masses of 52 and 55 kDa. In different cells, such as rat eryth-
rocytes, pituitary cells, astrocytes, and mouse neuroblastoma
cells, uptake of T4 and T3 appears to be mediated largely by
system L or T amino acid transporters. Efflux of T3 from dif-
ferent cell types is saturable, but saturable efflux of T4 has not
yet been demonstrated. Saturable uptake of T4 and T3 in the
brain occurs both via the blood-brain barrier and the choroid
plexus-cerebrospinal fluid barrier. Thyroid hormone uptake
in the intact rat and human liver is ATP dependent and rate
limiting for subsequent iodothyronine metabolism. In starva-
tion and nonthyroidal illness in man, T4 uptake in the liver is
decreased, resulting in lowered plasma T3 production. Inhi-
bition of liver T4 uptake in these conditions is explained by
liver ATP depletion and increased concentrations of circulat-
ing inhibitors, such as 3-carboxy-4-methyl-5-propyl-2-furan-
propanoic acid, indoxyl sulfate, nonesterified fatty acids, and
bilirubin. Recently, several organic anion transporters and L
type amino acid transporters have been shown to facilitate
plasma membrane transport of thyroid hormone. Future re-
search should be directed to elucidate which of these and
possible other transporters are of physiological significance,
and how they are regulated at the molecular level. (Endocrine
Reviews 22: 451–476, 2001)
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I. Historical Introduction
EARLY REPORTS ON uptake of thyroid hormones bycells and tissues of different species appeared in the
early 1950s. For about two and a half decades it was assumed
that the translocation of thyroid hormones over the plasma
membrane of target cells was a process of simple diffusion.
This assumption was based on the fact that thyroid hormones
are lipophilic and, as the plasma membrane is constituted of
a lipid bilayer, there seemed apparently no need to assume
any other mechanism of translocation than that of diffusion.
The belief in this concept was so strong that hardly any
studies testing this assumption were performed in this pe-
riod of time. The studies that were performed on thyroid
hormone uptake by cells and tissues were predominantly
directed at investigating the influence of temperature, pH,
and extracellular thyroid hormone-binding proteins on the
kinetics of this process. In the interpretation of the results of
these studies, it was often taken for granted that thyroid
hormones diffuse into the cells and that the driving force of
this process is the concentration of the free hormone. This
so-called “free hormone hypothesis” was formulated in 1960
by Robbins and Rall (1). They stated “that the free or dif-
fusible thyroid hormone concentration in blood and extra-
cellular tissues would determine the rate at which thyroid
hormone is distributed to its loci of action and the rates at
which it is degraded and excreted.” As we will see in the
following sections, this assumption is only partially correct.
Plasma membrane translocation is a regulated process that
is rate limiting for subsequent intracellular accumulation,
action, and fate of the hormone. However, we will also see
that, at least in vitro, the rate of uptake of thyroid hormones
into the cell is determined not only by the efficacy of this
plasma membrane translocation process but also by varia-
tions in the free hormone concentration in physiological and
pathophysiological conditions. In vivo the situation is more
complicated in that circulating inhibitors of thyroid hormone
tissue uptake may be operative as well.
It is remarkable that, to the best of our knowledge, the first
publication on thyroid hormone transport points to an en-
ergy-dependent uptake process (2). In this report, transport
of T3 into ascites carcinoma cells was inhibited by KCN, a
metabolic blocker that suppresses ATP formation, indicating
that energy is involved in the uptake mechanism. The au-
thors of this study concluded that “this amino acid does not
escape the cellular concentration process to which all other
amino acids so far studied are subjected.” This report ap-
parently escaped attention and was “rediscovered” by So-
rimachi and Robbins in 1978 (3).
In a review in 1957 (4), Robbins and Rall proposed that
thyroid hormone action is a function of the free hormone in
the blood. However, in view of the extremely low concen-
tration of unbound T4 in blood, they suggested that tissues
are extraordinarily sensitive to thyroid hormone, or that T4
has to be concentrated in target cells. This latter suggestion
leaves open the possibility of an active transport process. On
the basis of their studies using tissue slices at different in-
cubation temperatures and metabolic activities, Freinkel et al.
(5) concluded that the establishment of concentration differ-
entials for T4 between tissue slices and suspending media
constitutes an equilibrium-binding phenomenon rather than
an active transport. Hogness et al. (6) suggested that the
higher concentration of T4 and T3 in rat diaphragm as com-
pared with that in the incubation media was evidence for a
true chemical binding. They did not consider the possibility
of energy-dependent transport against a concentration gra-
dient. Two groups of investigators, Beraud et al. (7) and
Ingbar and Freinkel (8), were of the opinion that extra- and
intracellular thyroid hormone binding-proteins govern
transmembrane transfer of free diffusible hormone. In their
studies of the uptake of T4 and T3 by rat diaphragm, Lein and
Dowben (9) assumed that the kinetics of uptake they ob-
served were based on diffusion into the tissue and subse-
quent binding of hormone to intracellular proteins. In his
review on distribution and metabolism of thyroid hormone,
Tata (10) suggested that the plasma membrane did not play
an active role in the movement of free hormone from the
vascular to the tissue compartments. Hillier (11) published a
series of studies related to uptake and release of T4 and T3 in
different organs. To our knowledge, he was the first to assess
saturability of these processes. Studying the perfused rat
heart, saturation of these processes could not be detected
using free hormone concentrations ranging from 13 pm to 1.3
m. As we will see below (Sections II and III), the highest
concentration used is sufficient to saturate the high-affinity
component of the uptake process detected in rat hepatocytes
and many other cell types, although discrepancies have been
described. One of the reasons why any saturation of the
uptake mechanism might have escaped detection is that the
conditions under which the studies were performed were not
optimal to maintain intracellular ATP concentrations. This
means that any energy-dependent, carrier-mediated process
might have become undetectable. This possibility is in line
with another observation from the same study (11), that
thyroid hormone uptake was independent of changes in
incubation temperature. In a follow-up study (12), Hillier
concluded that extracellular thyroid hormone binding-pro-
teins are an important factor determining the total amount of
hormone taken up by the rat heart. Studying uptake and
release of T4 and T3 in rat liver under similar “ATP-poor”
conditions and using hormone concentrations up to 0.13 m,
he arrived at similar conclusions, in that uptake and release
were temperature independent and that uptake was impor-
tantly influenced by extracellular hormone-binding sites
(13). The assumption that thyroid hormones easily penetrate
plasma membranes was strengthened by Hillier’s next stud-
ies (14) using liposomes prepared from egg-yolk lecithin. He
reported that these membranes were readily permeable to T4
and that the binding of both T4 and T3 to liposomes and to
rat heart tissue is similarly dependent on pH.
In summary, until 1970 it was generally believed that
thyroid hormones enter target cells by simple diffusion. This
assumption was based on the fact that thyroid hormones are
lipophilic and could therefore easily traverse the lipid-rich
bilayer of the cell membrane. Transport of thyroid hormones
into cells was envisaged to be mainly regulated by binding
forces of extra- and intracellular thyroid hormone-binding
proteins, directing the free moiety of thyroid hormone pas-
sively through the plasma membrane.
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II. Binding of Thyroid Hormones to Isolated
Cell Membranes
A. Binding kinetics
The earliest studies analyzing specificity of binding of
thyroid hormones to plasma membranes of target cells were
reported in 1975 by Tata (15) and in 1976 by Singh et al. (16).
Although detecting saturability of binding of thyroid hor-
mones to different cellular constituents, including plasma
membranes, Tata questioned the biological relevance of these
binding sites (15). Singh and his group studied inhibition of
binding of T3 and T4 to intact hemoglobin-free erythrocyte
membranes by thyroid hormone analogs (16). Specificity of
binding was demonstrated for both T4 and T3 by structure-
dependent inhibition by the analogs. The major finding of
this study was that the avidity of erythrocyte membranes
was greater for T3 analogs than for T4 analogs but was similar
for l-T3 and l-T4.
Several reports concerned binding of thyroid hormones to
plasma membranes of rat hepatocytes (17–20). Pliam and
Goldfine (17) reported on two binding sites for l-T3, one with
high affinity and low capacity and one with low affinity and
high capacity. Mean apparent dissociation constant (Kd) val-
ues were 3.2 nm and 220 nm, respectively (Table 1). Similar
values were found by others (18), who also reported on high-
and low-affinity binding sites for l-T4, with mean apparent
Kd values of 0.57 nm and 23.8 nm, respectively, distinct from
the T3 binding sites (Table 1). Specific T4 binding was inhib-
ited by thiol-blocking agents and by proteases. l-T4 was
bound with high specificity regarding iodine substituents
and alanine side chain modifications (20). Studies of l-rT3
binding to rat hepatocyte membranes also revealed two
binding sites, the high-affinity site being different from that
of l-T4 (21).
A number of studies have also reported on the binding of
thyroid hormones to human and rat erythrocyte membranes
(22–29). Both in human and rat erythrocyte membranes, two
saturable binding sites for l-T3 were identified; a high-
affinity, low-capacity and a low-affinity, high-capacity bind-
ing site. Apparent Kd values for the high-affinity binding site
in human erythrocytes varied between 0.2 nm and 140 nm
and for the low-affinity binding site between 5 nm and 26 m
(22, 24, 25, 27). Specific binding was dependent on the pres-
ence of reduced protein-SH groups and showed high spec-
ificity for l-T3, with l-T4 being far less avidly bound (24). For
rat erythrocyte membranes, apparent Kd values for T3 varied
between 9 pm and 21 nm for the high-affinity site and be-
tween 0.4 nm and 50 m for the low-affinity site (23, 26–29)
(Table 1). Also here, specific binding was dependent on the
reduced state of protein–SH groups, and the high-affinity
binding site appeared to be related to the amino acid trans-
port system T (27, 28). Binding was (stereo)specific, in that
d-T3 and l-T4 were less potent in competing for these sites
than l-T3, whereas rT3 and triiodothyroacetic acid were in-
active (23). The considerable variation in apparent Kd values
reported in these studies is probably due to differences in test
conditions and techniques, but may also be caused by in-
volvement of multiple transporters (see Section IX).
Binding of thyroid hormones to plasma membranes of
other cell types and species was also reported. High-affinity
binding sites for T3 and T4 in plasma membranes of rat
kidney and testis were characterized by apparent Kd values
in the low nanomolar range, whereas those of the low-
affinity binding sites were in the high nanomolar range (Ta-
ble 1). Specific binding sites for l-T3 and l-T4 could not be
detected in rat spleen (18). In plasma membranes of human
placenta, two specific l-T3 binding sites were found with
apparent Kd values of 2.0 nm and 18.5 m (30). d-T3, l-rT3,
l-T4, and d-T4 were less effective in displacing l-T3 from both
binding sites. In plasma membranes of a mouse neuroblas-
toma cell line, l-T3 binding sites showed apparent Kd values
of 8.4 nm and 7.3 m, with lower affinity of both sites for
d-T3 (31).
B. Analysis of binding protein(s)
A series of publications by Cheng and co-workers (30,
32–35) concerned the identification of T3 and/or T4-binding
membrane proteins in different cell types by affinity-labeling
techniques. In their experiments using human placenta (30),
GH3 cells (32, 33), mouse Swiss 3T3 fibroblasts (33), and
human A431 epitheloid carcinoma cells (33), the proteins
were envisaged to be associated with the plasma membrane
and to have a molecular mass between 55 (32, 33) and 65 kDa
(30). Peptide mapping of the proteins labeled with N-bro-
moacetyl-[125I]T3 (BrAc[
125I]T3) or BrAc[
125I]T4 showed very
similar patterns (33), indicating that the same protein was
probably involved. Later immunocytochemical studies, us-
ing four different monoclonal antibodies against the 55-kDa
thyroid hormone-binding protein, showed that this protein
was loosely associated with the endoplasmic reticulum and
nuclear envelope, although some association with the
plasma membrane could not be excluded (34). In a later study
by Kato et al. (35), this protein was shown to be identical to
protein disulfide isomerase (PDI). This finding was con-
firmed by Horiouchi et al. (36), who detected both T3-binding
TABLE 1. Specific binding of L-T3 and L-T4 to isolated plasma
membranes of different tissues from different species (mean
values)
Tissue
T3 T4
Ref.
Kd1a Kd2b Kd1a Kd2b
Rat hepatocytes 3.2 nM 220 nM 17
Rat hepatocytes 15 nM 270 nM 0.57 nM 23.8 nM 18
Rat hepatocytes 15.8 nM 237 nM 4.54 nM 127.0 nM 18
Rat kidney 10 nM 19
Human erythrocytes 140 nM 26 M 22
Human erythrocytes 0.2 nM 5 nM 24
Human erythrocytes 34 nM NDc 25
Human erythrocytes 0.2 nM 18 M 27
Rat erythrocytes 19 pM 20 nM 23
Rat erythrocytes 9 pM 0.4 nM 26
Rat erythrocytes 20 pM NDc 27
Rat erythrocytes 21 nM 50 M 28
Rat erythrocytes 4.5 nM NDc 29
Rat testis 266.0 nM NDc 27.77 nM 285.7 nM 18
Rat spleen NDc NDc NDc NDc 18
Human placenta 2.0 nM 18.5 M 30
Mouse neuroblasts 8.4 nM 7.3 M 31
a High-affinity binding site.
b Low-affinity binding site.
c Not detected.
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and PDI activity in a 55-kDa protein isolated from a plasma
membrane-enriched beef liver fraction. Although some PDI
may indeed be associated with the plasma membranes, most
of this enzyme is located in the lumen of the endoplasmic
reticulum (37). In contrast to the high reactivity of PDI to-
ward BrAcT3 and BrAcT4, it shows only low affinity for
underivatized T3 and T4 (38). Since, moreover, PDI is not an
integral membrane protein (37, 38), it seems unlikely to be
involved directly in plasma membrane transport of thyroid
hormone.
Photoaffinity labeling of erythrocyte membranes with l-T3
has identified a protein with an apparent molecular mass of
55 kDa (39). T3 binding to this protein was critically depen-
dent on the presence of phospholipids. Tryptophan but not
leucine or d-T3 competed with the l-T3 binding site, indi-
cating stereospecificity and a possible relationship with the
amino acid transport system T (39). Using a monoclonal
antibody that specifically inhibited uptake of T3 in rat hepa-
tocytes, a putative carrier protein was detected with an ap-
parent molecular mass of 52 kDa (40). Affinity labeling of
mouse neuroblastoma plasma membranes with BrAc[125I]T3
has detected a 27-kDa protein (31). Since the size of this
protein is identical to that of the type I iodothyronine deio-
dinase, which is also readily labeled with BrAcT3 (38), it is
unlikely to be related to a thyroid hormone transporter.
In summary, the first studies showing specific binding of
thyroid hormones to isolated cell membranes appeared in the
mid-1970s. Most extensively studied were cell membranes
from human and rat erythrocytes and rat hepatocytes. For
each T3 and T4, two stereospecific binding sites were detected
in these membranes; one with apparent Kd values in the
lower nanomolar range, and the other in the (sub)micromo-
lar range. Specific binding for both hormones was dependent
on the reduced state of protein-SH groups. T3-binding pro-
teins have been identified in rat erythrocyte and hepatocyte
membranes with apparent molecular masses of 55 and
52 kDa.
III. Transport of Thyroid Hormones into
Isolated Cells
The first evidence, to our knowledge, that transport of
thyroid hormones into intact cells is not a passive, but an
energy-dependent, process was reported by Christensen et al.
in 1954 (Ref. 2; see also Section I) but unfortunately tempo-
rarily escaped attention. It was not until 1976 that Rao et al.
(41) and our laboratory (42, 43) in 1978 independently pub-
lished the saturable and energy-dependent transport of T3
and T4 into rat hepatocytes. Since then a whole series of
reports from different laboratories have confirmed carrier-
mediated, mostly energy- and Na-dependent transport of
iodothyronines into a variety of cells from different species.
A. Transport into hepatocytes
In Table 2 the kinetics of thyroid hormone uptake by
hepatocytes are summarized. In most studies two saturable
processes have been discerned: a high-affinity, low-capacity
and a low-affinity, high-capacity process (41–55). In the ma-
jority of the studies, the apparent Km values of the high-
affinity systems for T4, T3, or rT3 uptake are in the nanomolar
range (42–55). This process is thought to represent the trans-
location process across the plasma membrane as it is energy
and temperature dependent (41–55). Studies testing the pos-
sible Na dependence of the high-affinity uptake of iodo-
thyronines have produced controversial results in rats (44–
47, 50), confirmatory results in human hepatocytes (52), and
negative results in trout hepatocytes (54, 55). The energy-,
temperature-, and Na-independent, low-affinity uptake
process may represent binding of thyroid hormone to cell
surface-associated proteins (45). T4 and T3 mutually inhibit
their high-affinity uptake processes in rat hepatocytes, but
kinetic analysis of these inhibitions indicates that T3 and T4
cross the plasma membrane by different pathways (47, 55).
This finding was confirmed by others who found differences
in the dependence of the T3 and T4 transport systems on the
cell phase of the rat hepatocyte and on sodium butyrate
stimulation (56). Preliminary results in rat hepatocytes sug-
gest that rT3 shares the same transport system with T4 (48),
but kinetic studies of plasma iodothyronine clearance in hu-
mans suggest different plasma-to-liver transfer mechanisms
for rT3 and T4 (57), in line with different binding sites for rT3
and T4 in (rat) liver plasma membrane (21). In addition to the
metabolic condition of hepatocytes in culture, in particular
with regard to ATP concentration, the free T4 concentration
in the medium is also a determinant for the amount of hor-
mone that is taken up by the cell and subsequently metab-
olized (58). Stereospecificity of T3 and T4 uptake has been
demonstrated in rat and trout liver cells (51, 54, 55).
B. Transport into other cell types
Many studies have confirmed carrier-mediated, often en-
ergy- and Na-dependent transport of thyroid hormones in
various cell types from different species, i.e., human (22,
59–62), rat (63–65), and trout (66, 67) erythrocytes; normal
(68, 69) and clonal (70) rat pituitary cells, brain cells such as
human glioma cells (71), rat glial cells (72), astrocytes (73),
cerebrocortical neurons (74), and brain synaptosomes (75);
mouse neuroblastoma cells (76), rat skeletal (77) and cardiac
(78) myocytes; human (79, 80) and mouse (81) fibroblasts;
human epithelial carcinoma cells (81); Chinese hamster
ovary cells (81); human trophoblasts (82); human choriocar-
cinoma cells (83–86); rat adipocytes (87); human peripheral
leukocytes (88, 89); and mouse thymocytes (90, 91) (Table 3).
1. T3 transport. Similar to hepatocytes, apparent Michaelis-
Menten (Km) values for the high-affinity uptake of T3 in other
cell types are mostly in the nanomolar range. Some authors
(22, 73), including our laboratory (80), have also detected a
low-affinity T3-binding site, like that present on hepatocytes,
apparently depending on the use of protein (albumin)-
containing incubation media and probably reflecting the as-
sociation of protein-bound T3 with/around the cells (45).
When studied, the energy dependence of T3 transport was
invariably demonstrated in the different cell types. In con-
trast, the Na dependence of this process differed between
cell types. Thus, transport of T3 in erythrocytes of human, rat,
and trout origin (22, 59–67), in rat astrocytes (72, 73), and
human choriocarcinoma cells (82–86) was not dependent on
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the Na gradient over the plasma membrane, whereas this
was the case in rat pituitary cells (68–70), rat brain synap-
tosomes (73), rat neonatal cardiac myocytes (78), human fi-
broblasts (80), and mouse thymocytes (90, 91). In some cell
types the influence of pH on transport was studied and found
to be of importance, in the sense that T3 uptake decreased
when pH increased in mouse thymocytes (91), while the
reverse was true in rat brain astrocytes (75). When studied,
T3 transport was invariably (stereo)specific, i.e., in human
and rat erythrocytes, human and rat nerve and brain cells, rat
skeletal myoblasts, human choriocarcinoma cells, and mouse
thymocytes (Table 3). In general, different l-iodothyronine
analogs and the d-isomers of T3 and T4 were less potent in
inhibiting T3 and T4 uptake than l-T3 and l-T4.
2. T4 transport. T4 transport into intact cells has been less well
studied than T3 transport (Table 3). The most probable ex-
planation for this, at least in liver cells, is the greater re-
quirement of an optimal energy charge of the cells under
study for transport of T4 than for uptake of T3. This is ex-
plained by the much steeper slope of the relationship be-
tween cellular ATP concentration and the rate of T4 (and rT3)
transport in hepatocytes than that of the relationship be-
tween ATP and T3 transport (Fig. 1) (46). Even a small de-
crease in cellular ATP concentration results in a major re-
duction in T4 (and rT3) transport but only slightly affects T3
uptake. This may also be the reason why some authors could
not observe specific, energy-dependent transport of T4 in
liver cells (44, 92). Others (93) did find saturable but energy-
independent uptake not only of T4 but also of T3 in rat
hepatocytes under far from optimal cellular ATP conditions.
In other cell types, such as erythrocytes, rat neonatal cardiac
myocytes, rat brain cells, pituitary cells, and fibroblasts, some
laboratories observed that, in contrast to T3, T4 was appar-
ently taken up by diffusion only or not at all, whereas other
laboratories did find (stereo)specific, mostly energy-depen-
dent T4 uptake in the same cell types (Table 3). It is not known
whether these discrepancies are related to the different en-
ergy requirements of the T4 and T3 transport processes as
mentioned above or due to other factors such as the use of
different techniques.
C. Interactions of various compounds with thyroid
hormone transport
1. Amino acids. Interrelationships between amino acid and
thyroid hormone transport have been studied in different cell
types from different species. It should be noted that the
effects of amino acids on thyroid hormone transport cited
below were usually obtained at physiological serum con-
centrations of free amino acids in the micromolar range.
a. Erythrocytes. In rat erythrocytes, the aromatic amino
acids tryptophan (Trp), phenylalanine (Phe), and tyrosine
(Tyr) competitively inhibited T3 transport, while transport of
Trp was similarly inhibited by T3, d-T3, T4, and thyronine (T0)
(94). N-ethylmaleimide (NEM) irreversibly inhibited Trp and
T3 transport, and both ligands protected each others trans-
port from inactivation by this compound. These data indi-
cated common or closely linked transport systems for T3 and
for aromatic amino acids, i.e., the system T amino acid trans-
porter, at least in erythrocytes (94). Similar results were ob-
tained for binding of T3 and Trp to rat erythrocyte mem-
branes (28). Further studies suggested a common carrier for
T3 and Trp, which also facilitates countertransport such that
the uphill transport of T3 is driven by heteroexchange with
intracellular aromatic amino acids (95). Evidence for uptake
of T3 by the system T amino acid transporter or a closely
linked transporter was also obtained using human and trout
erythrocytes (62, 67). No such relationship was found be-
tween T4 and system T amino acid transport in trout eryth-
rocytes (67).
b. Other cell types. In rat hepatocyte sinusoidal membrane
vesicles, Trp transport occurs via a NEM-resistant (system T)
and a NEM-sensitive (system L) pathway, and T3 and T4
mainly inhibit Trp transport via system T (96). The inhibitory
TABLE 2. Kinetics of thyroid hormone transport into hepatocytes in vitro (mean values)
Species Km T4 Km T3 Km rT3
Temperature
dependent
Energy (ATP)
dependent
Na
dependent
Stereo-
specific Ref.
Rat
1a 52 nM Yes Yes 41
2b 144 nM Yes Yes
Rat
1a 1.2 nMc 21 nMc Yes Yes Yes 42,45–47,50
2b 1.0 M 1.8 M No No
Rat
1a 86 pM Yes Yes No 44
2b 726 pM Yes Yes No
Rat 6 nMd Yes 48
Rat hepatoma 680 nM Yes Yes 51
Human NRe Yes Yes Yes 52
Human
1a 3.6 nM Yes 53
2b 503 nM
Trout 0.52 Ma 74 nMa Yes No Yes 54,55
a High-affinity uptake system.
b Low-affinity uptake system.
c T4 and T3 have different transport systems.
d rT3 transport system possibly shared with T4.
e Not reported.
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activity of T3 and T4 is dependent on the thyroid status of the
donor rat, i.e., decreasing in the order hyperthyroid  eu-
thyroid  hypothyroid. T3 and T4 share the same stereospe-
cific uptake carrier in the rat pituitary (68, 69), and the potent
inhibition of T3 and T4 uptake by leucine (Leu) suggests the
involvement of amino acid transport system L (70). This
system was also found to participate in T3 and T4 transport
in mouse neuroblastoma cells (74) and in T3 transport in rat
astrocytes (97). In Ehrlich ascites cells, the neutral amino
acids Phe, -aminoisobutyric acid, and cycloleucine did not
compete with transport of T4, indicating that the system A,
L, and ASC amino acid pathways were not involved (98). In
rat hepatocytes, participation of the amino acid transport
system A in uptake of T3 and T4 was ruled out (51, 99). A
weak interaction was found between uptake of system L and
T amino acids and uptake of T3 in human JAR choriocarci-
noma cells (100).
2. Drugs and other chemicals. As shown in Table 4, a variety
of compounds has been demonstrated to inhibit thyroid hor-
mone uptake in different cells. Despite their widely different
properties, the inhibitory activity of most of these substances
is suggested to be based on competition because of structural
similarity with thyroid hormone (19, 48, 51, 53, 101, 103–107,
111, 112). The antiarrhythmic drug amiodarone is also
known to inhibit binding of T3 to its nuclear receptors on the
basis of structural similarity (114). The concentration of ami-
odarone shown to inhibit uptake of thyroid hormone in rat
hepatocytes was 1 m, which is similar to therapeutical
serum levels in humans (114). However, since in serum,
amiodarone is primarily bound to albumin that circulates at
a concentration of 4% but was used in the hepatocyte
incubations at a concentration of 1%, the free amiodarone
concentrations obtained in vitro may be higher than in treated
humans. Nevertheless, in vivo kinetic data in patients treated
with amiodarone also show decreased net tissue uptake of
thyroid hormone (115). This decrease can be explained by
inhibition of thyroid hormone transport into tissues and/or
by inhibition of thyroid hormone binding to intracellular
proteins. Cholecystographic agents usually reach serum con-
centrations between 100 and 700 m in humans (116) and
were tested in vitro (at lower albumin levels) at concentra-
tions between 10 and 100 m (48). These agents not only
inhibit thyroid hormone transport into rat hepatocytes, sup-
posedly on the basis of molecular structural similarity (19,
TABLE 3. Kinetics of thyroid hormone uptake in different cell types in vitro (mean values)
Cells Km T4 Km T3
Temperature
dependent
Energy (ATP)
dependent
Na
dependent
Stereo-
specific Ref.
Human erythrocytes
1a 16 nM Yes 22
2b 3.3 M No
Human erythrocytes 128 nM No No 59
Human erythrocytes 248 nM 60
Human erythrocytes Diffusion? 67 nM No No Yes 61
Human erythrocytes 59.9 nM 62
Rat erythrocytes No uptake 53 nMc Yes No Yes 63,64
Rat erythrocytes 160 nM 65
Trout erythrocytes 0.1–1.1 nM 70–119 nM Yes No No 66,67
Rat pituitary NRd 400 nMe Yes Yes Yes 68–70
Human glioma cells 0.46 nM 2.17 nM Yes Yes Yes 71
Rat astrocytes 1.02 Mg 0.52 Mg No No Yes 72,75
Rat brain synaptosomes
1a Diffusion? 50 pM Yes Yes Yes 73
2b 3.1 nM
Mouse neuroblastoma 6.07 nM 2.38 nM Yes Yes 74
Rat brain neurons 300 nMf 400 nMf Yes 76
Rat skeletal myoblasts 17 nM Yes Yes Yes 77
Rat neonatal cardiac myocytes Diffusion? NRd Yes Yes 78
Human fibroblasts Diffusion? 108 nM 79
Human fibroblasts
1a 1.9 nM 29 nM Yes Yes 80
2b 141 nM 650 nM
Mouse fibroblasts NRd Yes 81
Human epithelial carcinoma NRd Yes 81
Hamster ovary NRd Yes 81
Human trophoblasts 755 nM 82
Human choriocarcinoma 59.4 nMh 378–586 nMh Yes Yes No Yes 83–86
Rat adipocyte 0.30 nM 0.29 nM 87
Human leukocytes NRd 88,89
Mouse thymocytes Diffusion? 0.8 nM Yes Yes Yes 90,91
a High-affinity uptake system.
b Low-affinity uptake system.
c trans-Inhibition of T3 in- and efflux by T3.
d Not reported.
e T4 and T3 share same transport system.
f T4 and T3 have different transport systems.
g Na-H exchanger dependent.
h Km rT3 3.04 M.
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48), but also displace T4 from the human liver in vivo (117).
The non-bile acid cholephils, sulfobromophthalein, bilirubin,
and indocyanine green, also inhibit thyroid hormone trans-
port and binding in rat hepatocytes on the basis of structural
similarity (19, 51). Diphenylhydantoin, the nonsteroidal an-
tiinflammatory phenylanthranilic acids, flufenamic acid,
meclofenamic acid, and mefenamic acid, and the structurally
related compounds, 2,3-dimethyldiphenylamine and di-
clofenac, all competitively inhibit rat hepatocyte and pitu-
itary uptake of thyroid hormone (51, 107, 111, 113). Analysis
of the structure-activity relationship for inhibition of T3 up-
take in rat hepatocytes by the phenylanthranilic acids dem-
onstrated that inhibitory potency was highly dependent on
the hydrophobicity of the inhibitor (107). Phloretin, a glucose
FIG. 1. Uptake of T3 (F), rT3 (‚), and T4
() vs. ATP concentration in rat hepa-
tocytes preincubated with different con-
centrations of glucose or fructose. [Re-
produced with permission from E.P.
Krenning et al.: FEBS Lett 140:229–
233, 1982 (48).]
TABLE 4. Chemical inhibitors of thyroid hormone uptake into cells in vitro
Inhibitor Cell type Ligand Supposed mechanism ofinhibition Ref.
Ouabain, monensin Rat hepatocytes, rat
skeletal muscle, pituitary
T3 Abolition Na
 gradient 48,49,68
KCN, dinitrophenol bacitracin, oligomycin Rat hepatocytes, mouse
thymocytes
T3, T4 ATP depletion 48,90
Vinblastin, colchicin cytochalasin Rat hepatocytes, mouse
thymocytes
T3, T4 ATP depletion 
perturbation cytoskeleton
48,90
D- and L-propranonol Rat hepatocytes, mouse
thymocytes
T3, T4 ATP depletion  membrane
stabilization
48,90
Amiodarone Rat hepatocytes T3, T4 Competitive 48,114
Cholecystographic agents Rat hepatocytes T3, T4 Competitive 20,51
Nifedipine, verapamil, diltiazem Rat hepatocytes, rat
myoblasts, human
hepatocytes
T3 Interaction with calmodulin
(like-protein)
101,112
Bromosulphthalein, indocyanine green Rat hepatocytes, rat brain
astrocytes
T3, T4
T3, T4
Competitive 19,51
Bilirubin and conjugates Rat hepatocytes T3 ? 106,109
Diphenylhydantoin, phenylanthranilic acid,
and phenylacetic acid derivatives
Rat hepatocytes, rat
pituitary
T3 Competitive 51,107,111,113
Phloretin Human hepatocytes T3 Competitive 53
3,5-Dibromo-3-pyridazinone-L-thyronine
(L-94901)
Rat myoblasts, rat
hepatocytes, rat
neuroblasts
T3 Un- or noncompetitive 102
Benzodiazepines Human hepatocytes, human
neuroblast, rat pituitary
T3 Direct or indirect interaction
with T3 carrier
103–105
CMPF, indoxyl sulfate Rat hepatocytes T4 Unknown 108
NEFA Rat hepatocytes T4 Unknown 109,110
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transporter inhibitor that is structurally related to thyroid
hormones, competitively inhibited T3 uptake into human
HepG2 hepatocarcinoma cells (53). Many of the inhibitors of
thyroid hormone uptake discussed here also interact com-
petitively with thyroid hormone-binding sites on serum pro-
teins and nuclear T3 receptors (51, 107, 113, 118). Amioda-
rone, cholecystographic agents, and bilirubin have been
shown to interact with deiodinases (114, 119). The benzodi-
azepine drugs do not interact with nuclear T3-binding sites,
but inhibit T3 uptake in different cell types from human and
rat origin (Table 4) by competing for the T3 carrier without
being transported themselves (104). The structure-activity
relationships were studied for inhibition of T3 uptake in
HepG2 cells by benzodiazepine and thyromimetic com-
pounds. The results of these studies, along with computer-
assisted molecular modeling techniques, predicted a “tilted
crossbow” conformation of the inhibitor for interaction with
the iodothyronine transporter (105).
The three different types of organic calcium channel block-
ers, nifedipine, verapamil, and diltiazem, inhibit T3 uptake in
different cell types (Refs. 101 and 112; Table 4). It is consid-
ered unlikely that the inhibitory effect is due to dependence
of the uptake process on extracellular Ca2, on Ca2 fluxes
via voltage-dependent or receptor-operated calcium chan-
nels, or on the interaction of Ca2 with PKC. A plausible
mechanism for the inactivation of the uptake process is by
interaction of the calcium blockers with calmodulin in the
plasma membrane. Calmodulin is found in high concentra-
tions in plasma membranes; it binds T3 and may play a role
as such in the translocation process of thyroid hormone
(101). 3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid
(CMPF), indoxyl sulfate, and nonesterified fatty acids
(NEFAs) are substances that circulate in increased amounts
in patients with nonthyroidal illness (NTI) and inhibit thy-
roid hormone uptake in liver cells (Refs. 108–110; see Section
VII.B).
Little information is available about stimulatory factors of
thyroid hormone uptake in vitro. The histamine H1 receptor
antagonist, telemastine, and phenobarbital enhance the spe-
cific, energy-dependent uptake of T4 in rat hepatocytes but
not in hepatocytes from guinea pig or beagle dog (120). The
exact mechanism of this induction in rat hepatocytes is un-
known but appears to be a primary effect on the plasma
membrane transport system. Telemastine did not influence
T3 uptake in rat hepatocytes, underscoring the functional
difference in the uptake systems of T3 and T4 in the liver (121).
In summary, transport of T4 and T3 has been studied ex-
tensively in human, rat, and trout hepatocytes. For both T4
and T3, high-affinity, low-capacity and low-affinity, high-
capacity uptake processes have been identified. The high-
affinity processes have apparent Km values in the nanomolar
range and represent the translocation of the hormones over
the plasma membrane. This transport is temperature, energy,
and Na dependent, and rate limiting for subsequent hor-
mone metabolism. T4 and T3 mutually inhibit their high-
affinity uptake processes, but they are transported by dif-
ferent carriers. The low-affinity processes represent binding
to cell surface-associated proteins and are not involved in
transport. High-affinity, energy-dependent T3 transport sys-
tems similar to those in hepatocytes have also been identified
in many other cell types, although their Na dependence
varies. T4 transport has been less well studied in other cell
types, and results are variable, possibly because of its greater
requirement for an optimal energy charge of the cells.
T3 uptake in different cells (rat erythrocytes, pituitary cells,
astrocytes, and mouse neuroblastoma cells) is inhibited by
Trp, Phe, Tyr, and/or Leu, suggesting the involvement of
system L or T amino acid transporters. A large variety of
chemicals (Table 4) inhibit cellular uptake of thyroid hor-
mones on the basis of structural similarity or by decreasing
the cellular energy charge. Alternatively, inhibition is me-
diated by a decrease in the Na gradient over the plasma
membrane, or by other as yet unknown mechanisms. The
inhibitory activities of amino acids and other compounds are
in the concentration range observed in humans and may
interfere with in vivo tissue uptake of thyroid hormone.
IV. Cellular Efflux of Thyroid Hormones
Efflux of thyroid hormones has been studied in a number
of cell types from different species, i.e., hepatocytes (122–
124), erythrocytes (60, 61, 64, 125, 126), placenta cells (84, 127,
128), pituitary cells (129), FRTL-5 thyroid cells (130), NIH-3T3
cells (130), thymocytes (90), lymphocytes (131), and Ehrlich
ascites cells (98).
We reported on absence of energy dependence of T3 and
T4 efflux from cultured rat hepatocytes (122). Cellular efflux
consisted of two components, representing release of hor-
mone bound to the outer cell surface and of intracellularly
located hormone. We also observed a lack of saturability of
T3 efflux after loading of rat hepatocytes using free T3 con-
centrations up to 54 nm (122). However, further results sug-
gested saturation of T3 efflux after loading of the cells using
a free T3 concentration of 1.5 m. Others also observed satu-
rability of T3 efflux, by both T3 and T4, from a poorly dif-
ferentiated rat hepatoma cell line (HTC) (123). The same
authors also demonstrated that verapamil inhibited thyroid
hormone efflux from these cells as well as from isolated rat
hepatocytes, cardiomyocytes, and fibroblasts (123). Further-
more, they observed increased verapamil-inhibitable T3 ef-
flux from HTC cells adapted for resistance to a permeable
bile ester (HTC-R cells). The authors suggested that the car-
rier protein involved in export of thyroid hormone is related
to the family of the multidrug resistance-related ABC trans-
porters as these membrane proteins are overexpressed in
HTC-R cells (123). The same group also found verapamil
inhibition of T3 efflux from FRTL-5 thyroid cells and NIH-
3T3 cells (130). Others assessed T4 and T3 efflux from mul-
tidrug-resistant pituitary tumor cells but did not find kinetics
to be different from control pituitary tumor cells (129). Nei-
ther was any effect detected by verapamil on thyroid hor-
mone efflux in both cell types. Possible saturability of thyroid
hormone efflux was not tested by these authors (129).
Efflux of T3 from rat erythrocytes was found to be a sat-
urable process that is stimulated by aromatic amino acid
countertransport, much as T3 uptake is stimulated by counter
efflux of aromatic amino acids (61, 64). Efflux of T4 from these
cells occurred apparently by diffusion as is the case with T4
and rT3 efflux from human JAR choriocarcinoma cells, while
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also in these latter cells efflux of T3 is saturable (84, 128). No
inhibitory effect on thyroid hormone efflux by neutral system
A, L, and ASC amino acids was observed in Ehrlich ascites
cells (98). In many of the in vitro studies discussed in this
section, it has been shown that thyroid hormone-binding
proteins, including T4-binding globulin (TBG), transthyretin
(TTR), albumin, and lipoproteins have a permissive effect on
efflux of thyroid hormones, probably by facilitating diffusion
of thyroid hormone through the water layer around the cell
(122, 124, 126).
In summary, efflux of T3 from rat hepatocytes, cardiomy-
ocytes, and fibroblasts has shown to be a saturable but en-
ergy-independent process. The efflux carriers in these cells
may be related to the multidrug resistance-related ABC
transporter family. In rat erythrocytes, T3 efflux is also sat-
urable and is stimulated by aromatic amino acid counter
transport. Neither T4 efflux from these cells nor T4 and rT3
efflux from human JAR choriocarcinoma cells was found to
be saturable, in contrast to the saturable efflux of T3. Little is
known about the role of efflux mechanisms in the regulation
of intracellular hormone concentrations.
V. Transport of Thyroid Hormone into
Isolated Organs
Transport of thyroid hormones into perfused organs iso-
lated from animals has been extensively studied. The ad-
vantage of studying an isolated organ is that its function can
be evaluated without interference from other influences in
the intact organism. Compared with experiments using iso-
lated cells, the study of intact organs better represents the
function of the tissues in vivo, although conditions are still
appreciably different from the (patho)physiological situa-
tion. The results of thyroid hormone uptake studies using
perfused, isolated organs from different species will be dis-
cussed in this section.
A. Transport into the liver
Transport of thyroid hormones into the intact liver has
been mostly studied using organs isolated from rats. In 1979,
Jenning et al. (132) reported on the effect of starvation on T3
production from T4 taken up by the perfused rat liver. They
found that the reduced T3 production was not caused by
impaired deiodination of T4 to T3 in the liver but by reduced
transport of T4 into the liver, underlining the regulatory role
of transport of thyroid hormone in subsequent hormone
metabolism (132). One of the explanations that these authors
mentioned was that T4 uptake was inhibited by decreased
activity of a “specific” transport system. We extended these
studies to T3 and also found inhibition of T3 uptake in the
intracellular compartment of livers from fasted vs. normally
fed rats perfused with medium lacking glucose, insulin, and
cortisol (133). This inhibition was reverted to normal by a
30-min preperfusion of fasted livers with medium containing
a combination of glucose, insulin, and/or cortisol but not by
the individual additions. On the basis of these results, we
explained the diminished T3 uptake by a decrease in cellular
ATP induced by fasting, which was restored by preperfusion
with energy-rich medium (133). Further studies using fruc-
tose in the perfusate to (transiently) lower cellular ATP stores
in the rat liver showed a parallel decrease in T4 uptake in the
intracellular compartment of the liver, thus underscoring the
regulatory role of the energy charge of the cell in the trans-
port process (Fig. 2, Ref. 134). Similar to the results in cul-
tured rat hepatocytes, we found that, in addition to the en-
ergy state of the liver, the free hormone concentration in the
perfusion medium determined the amount of hormone taken
up by the intracellular compartment of the liver (135). Studies
using livers from amiodarone-treated animals indicated that
transport of T4, but not of T3, was inhibited (136), in agree-
ment with hepatocyte studies (47, 55) showing that T4 and T3
are transported differently across the liver plasma mem-
brane. Efflux of T3 from the isolated perfused trout liver was
stimulated by addition of T4, epinephrine, or TSH to the
perfusion medium, and efflux of T4 was stimulated by ad-
dition of T4 to the medium. The stimulating effect of extra-
cellular thyroid hormone on efflux of T4 and T3 may be
caused by inhibition of reuptake, stimulation of an exchange
mechanism, and/or displacement of hormone from intra-
cellular binding sites (137, 138). However, the stimulation of
T3 efflux by epinephrine and TSH remains unexplained.
B. Transport into other organs
As the choroid plexus is known to synthesize TTR (139,
140), the specific role that this tissue plays in transport of
thyroid hormone to brain cells was evaluated. Isolated cho-
roid plexus of the rat was found to accumulate T4 and T3 from
surrounding medium by a nonsaturable process (141). The
authors proposed a positive role of choroid plexus-derived
TTR in the transport of thyroid hormones from the blood to
the cerebrospinal fluid (CSF) and subsequently to brain cells.
Others found partly saturable uptake of T4 in the choroid
plexus of the rabbit (142). Measurement of T3 uptake at the
blood face of isolated sheep choroid plexus showed both
saturable and nonsaturable transport (143). T3 uptake lacked
stereospecificity and was Na independent, but was inhib-
ited by T4 and by large neutral amino acids. Uptake of T3 at
the CSF side of sheep choroid plexus was also partially sat-
urable and independent of the Na gradient over the plasma
membrane (143).
FIG. 2. T4 liver uptake (in % dose) in rat livers during glucose (F) and
glucose/fructose (Œ) perfusion. [Reproduced with permission from M.
de Jong et al.: Am J Physiol 266:E768-E775, 1994 (134).]
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Incubation of whole soleus muscle isolated from rats
showed stereospecific, energy- and Na-dependent uptake
of T3, but T4 uptake was considered to be a diffusion process
(49, 144). Addition of insulin to the incubation medium stim-
ulated T3 uptake but did not affect T4 uptake (145). T3 uptake
in the perfused rat heart showed a saturable process with an
apparent Km value of 80 m (146). This value is about 1 order
of magnitude higher than the apparent Km values obtained
in in vitro studies using isolated cardiomyocytes (Tables 2
and 3). This difference may be explained by the fact that T3
uptake in the perfused rat heart was determined after a single
capillary passage that proceeds within seconds and differs
fundamentally from techniques in which initial uptake rates
in cells are measured over a period of minutes. The question
is if the former method represents uptake of the ligand by the
cardiomyocytes, since this assumes that the hormone has
already passed the endothelium after such a short time lapse.
Another explanation, of course, is that the experiments using
cultured cells provide data that are more remote from the in
vivo situation than data obtained from isolated organ studies.
In contrast to the rat liver (132), fasting did not decrease
uptake of T4 by the isolated perfused rat kidney, but T4
uptake was decreased in kidneys of diabetic rats (147, 148).
In summary, uptake of T4 and T3 is decreased in isolated
livers from fasted vs. fed rats perfused with the same “en-
ergy-poor” medium. Changing the perfusate to an energy-
rich medium restores uptake in 30 min, suggesting restora-
tion of cellular ATP. Perfusion of fed livers with fructose
results in a lowering of cellular ATP and a parallel decrease
in thyroid hormone uptake. Analysis of transport in livers
from amiodarone-treated rats showed that in the intact liver,
T3 and T4 are also taken up by different mechanisms. Apart
from the cellular energy charge, the free and not the protein-
bound fraction of thyroid hormone determines the amount
of hormone taken up by the cellular compartment of the liver.
Uptake of T4 and T3 in isolated rat or sheep choroid plexus
was found to be nonsaturable by some investigators but
partly saturable by others. Saturable transport of T3, but not
of T4, was observed in the isolated rat soleus muscle. Satu-
rable T3 transport was also found in the perfused rat heart.
VI. In Vivo Plasma Membrane Transport of Thyroid
Hormones in Animals
To assess plasma membrane transport of thyroid hor-
mones to different organs in vivo, animals were injected with
tracer amounts of labeled hormones after which entry of
hormones into the isolated organs was analyzed.
A. Brain
Several questions related to transport of thyroid hormone
to the brain have been addressed. One aspect is whether
entry of thyroid hormone into brain proceeds via a passive
process or via a carrier-mediated mechanism. When dogs
were injected intravenously with tracer T4, allowing entry in
the brain via the blood-brain barrier (BBB) and the CSF, brain
uptake was saturable under conditions of T4 loading, indi-
cating that transport occurred via a carrier-mediated process
(149). In mice, transport of T3 into the brain was saturable but,
under the conditions of the experiment, no saturation of T4
transport was observed. Efflux of both T3 and T4 from the
brain appeared to proceed by a carrier-mediated mechanism
(150).
Another point of interest is to what extent transport
through the BBB and the choroid plexus-CSF barrier (CP-
CSFB) contributes to overall brain uptake of thyroid hor-
mone. To investigate this, rats were injected either intrave-
nously or intrathecally with radioactive thyroid hormones.
When administered intravenously, hormones have access to
the brain via both the BBB and the CP-CSFB. However,
hormone injected intrathecally represents entry into brain
cells via the CP-CSFB. After injection of radioactive hor-
mones via these two routes and subsequent autoradiography
of the brain, distribution of thyroid hormone over brain areas
could be documented as well as the contribution of the BBB
and the CP-CSFB to brain accessability (151–153). These stud-
ies demonstrated that T3 and T4 enter the brain mainly via the
BBB for distribution throughout the brain, but that localiza-
tion in the ependymal cells and in the circumventricular
organs occurs via the CP-CSFB. In contrast, rT3 is excluded
by the BBB but has limited access to the brain via the CP-
CSFB (Fig. 3).
Also, by in vivo injection of tracer hormones, the question
of whether TTR has a special role in transport of thyroid
hormone to the brain via the CP-CSFB was addressed. Re-
sults of studies in rats and sheep, showing accumulation of
thyroid hormone in the choroid plexus, led to the proposal
of a model for T4 transport from the bloodstream into the
CSF, involving uptake of T4 by the choroid plexus, binding
FIG. 3. Routes of iodothyronine transport between blood and brain.
According to autoradiographic results, rT3 crosses the CP-CSFB but
not the BBB, whereas T3 and T4 cross both BBB and CP-CSFB.
[Derived from Ref. 153.]
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of the hormone to newly synthesized TTR, and secretion
of the complex into the CSF (140, 154–156). Recent studies in
the TTR-null mouse mutant showed that total lack of TTR
seems to have no consequences for normal development and
fertility (157, 158). In these mice, serum levels of free T4, free
T3, and TSH were normal as were the type I and II deiodinase
activities (being very sensitive to the thyroid status of the
tissue) in liver and brain, respectively (157). Analysis of
tracer hormone kinetics showed that T4 tissue content of liver
and kidney was little affected, but was decreased in the brain.
T3 content of these tissues was normal. The low T4 content
of brain was explained on the basis of absence of TTR-T4
complexes, apparently without repercussion for normal local
T3 production from T4. These studies show that TTR is not
essential for sufficient transport of thyroid hormones into
brain and other organs. It seems that as long as the free
hormone concentration is kept constant, probably by virtue
of the presence of other thyroid hormone-binding proteins in
blood and other body fluids, no apparent harm is done to
tissue metabolism. In this respect, it is noteworthy that a
similar situation exists in humans with complete TBG defi-
ciency, who also show no apparent biological abnormality
(159). However, it is remarkable that genetic abnormalities
associated with complete TTR deficiency have so far not been
documented in humans or animals.
B. Other organs
The liver is another organ that has been studied in animals
for plasma membrane transport of thyroid hormone.
Pardridge et al. published a series of in vivo studies in the rat
(for review see Ref. 160). From their studies the authors
concluded that thyroid hormone delivery to the liver “occurs
via the free intermediate mechanism, i.e., protein-bound hor-
mone debinding is an obligatory intermediate step in the
transport process.” Although they found that transport of T4
into rat brain via the BBB is a saturable process, they could
not find saturability of plasma membrane transport in rat
liver, and suggested that this occurred via passive diffusion.
The authors used for their studies a single capillary pass
technique for analysis of initial kinetics of transport (160).
The model used by Pardridge et al. and their interpretation
of the data were strongly contested (161, 162). The main
criticism concerned the rate-limiting role in the transport
process that was attributed to the dissociation of hormone
from serum binding proteins. No such role could be envis-
aged, both on theoretical and experimental basis, by these
opponents. Others documented hepatic uptake in mice, in-
jected in vivo with radioactive T3, using autoradiography
(163). Excess unlabeled T3 resulted in 90% inhibition of liver
uptake of labeled T3. Time sequence autoradiographic anal-
ysis showed that the plasma membrane is initially labeled
before internalization of T3 occurs (163). These results clearly
document in vivo specific binding of T3 to the liver plasma
membrane as an initial step to internalization of the hor-
mone. In vivo injection of rats with radiolabeled T4 and sub-
sequent measurement of uptake in heart and lung tissue,
isolated at different time intervals, showed that T4 transport
in these organs was also saturable, in accordance with a
carrier-mediated transport mechanism (164).
In summary, brain entry of T4 in dogs appears to proceed
via a carrier-mediated mechanism. This was also found for
brain uptake of T3, but not of T4, in the mouse. It was further
shown in the rat that T3 and T4 mainly enter the brain via the
blood-brain barrier for distribution throughout the brain,
and via the CP-CSF barrier for restricted distribution in cir-
cumventricular areas. Although it has been envisaged for a
long time that TTR expressed in the choroid plexus plays an
essential role in the transport of thyroid hormones into the
brain, total lack of the protein in TTR knock-out mice has no
effect on concentrations of plasma free thyroid hormones and
TSH or on tissue thyroid hormone status. In vivo studies have
shown saturable T3 uptake into rat liver and saturable T4
uptake into mouse lung and heart.
VII. Plasma Membrane Transport in Humans
A. Introduction
In healthy individuals, about 80% of plasma T3 is produced
outside the thyroid gland, the remaining 20% being secreted
directly by the thyroid (165). In the extrathyroidal pathway,
T3 is produced by outer ring deiodination of T4, and in this
process the type I deiodinase in the liver (and kidneys) plays
an important role (165, 166). Another organ that may be
involved in this pathway in humans is skeletal muscle, ex-
pressing the type II deiodinase that also catalyzes the con-
version of T4 to T3 (167). To reach the intracellular T3-
producing enzymes, T4 must cross the plasma membrane of
these tissues. It has been established in rats that the extent to
which nuclear receptor-bound T3 is derived from plasma T3
and from local T3 production from T4 varies among the
tissues. Thus, for instance, nuclear T3 in cerebral cortex is
derived for80% from local conversion of T4, in pituitary for
50%, in skeletal muscle for40%, and in liver for only5%
(168, 169). In other words, for exertion of biological activity
by nuclear T3, both T4 and T3 must cross the plasma mem-
brane of target cells. It follows that the activity of these
transport processes may have an important influence on the
regulation of the biological activity of thyroid hormone. Al-
though the exact contribution of the different sources of
nuclear T3 in human tissues is unknown, it will also depend
to varying degrees on plasma membrane transport of T3 and
its precursor T4.
Many reports have dealt with the measurement of thyroid
hormone distribution and metabolism in humans. However,
few of these are concerned with analysis of unidirectional
transport of thyroid hormones into tissues. To study regu-
lation of biological processes, it is in general necessary to
analyze these under circumstances of perturbation of the
physiological steady state. This is certainly also true for the
study of the regulation of thyroid hormone transport into
tissues. Both in starvation and in so-called nonthyroidal ill-
ness (see Section VII.C), plasma T3 production is decreased.
As the diminution in plasma T3 production may be substan-
tial and thyroidal secretion of T3 contributes only little to total
plasma T3, the main cause of this diminution in T3 production
must consequently be located in the extrathyroidal pathway.
Both starvation and nonthyroidal illness have been used as
models to study regulation of thyroid hormone penetration
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into target tissues. Two possibilities have been suggested to
be responsible for the lowered T3 production in these situ-
ations, i.e., a decrease in outer ring deiodinase activity in
plasma T3-producing tissues and/or a decrease of T4 trans-
port into these tissues as substrate for T3 production. There
is evidence in animals, but not in humans (170), that outer
ring deiodination is indeed lowered in starvation and in
nonthyroidal illness, but this aspect will not be further dis-
cussed here. For further orientation, the reader is referred to
Ref. 171. In this section we will discuss plasma membrane
transport of thyroid hormones in human tissues both in
starvation and in nonthyroidal illness.
B. In starvation
In caloric deprivation, as in nonthyroidal illness (see Sec-
tion VII.C), abnormalities in serum thyroid function param-
eters are invariably present. The most constant and thus
characteristic abnormality is a low serum T3 concentration;
hence the term “low T3 syndrome” for this entity. Serum T4
and TSH are usually normal, whereas serum rT3 is usually
elevated (for a review see Ref. 172). To our knowledge the
first published study that was primarily designed to evaluate
unidirectional transport of thyroid hormones into tissues
before and during caloric deprivation in man was published
in 1986 by our laboratory (170). In this study T4 and T3
kinetics were studied using a three-pool model of thyroid
hormone distribution and metabolism in 10 obese but oth-
erwise healthy subjects before dieting and while on a 240-
kcal diet. During caloric restriction, unidirectional transport
of T4 and T3 into the rapidly equilibrating tissues (liver) was
decreased by 50% and 25%, respectively, when corrected for
changes in free hormone concentration. The decrease in
plasma T3 production amounted to 42%, about equaling the
reduction in T4 transport into the liver. T4-to-T3 conversion
rate decreased by an insignificant 8%. Therefore, the lowered
T3 production during caloric deprivation is largely, if not
fully, explained by a decrease of T4 entry into T3-producing
tissues. The fasting-induced decrease in liver T4 transport
may be explained, at least in part, by a decrease in the energy
charge of liver cells. This explanation is based on at least two
points. First, it has been shown that starvation leads to ATP
depletion of the liver as assessed by 31P-magnetic resonance
spectroscopy (173). Second, tissue T4 transport was much
more affected by caloric deprivation than transport of T3,
similar to findings of T4 and T3 transport in cultured rat
hepatocytes deficient in ATP (Ref. 48 and Fig. 1). To further
substantiate the effect of the intracellular ATP concentration
on hepatic T4 uptake in vivo in humans, liver T4 uptake was
measured in four healthy human volunteers, using T4 tracer
plasma kinetics, before and after an intravenous bolus in-
jection of fructose, which is known to transiently decrease
liver ATP levels. Obviously, hepatic ATP could not be mea-
sured, but fructose was found to induce an increase in serum
lactic acid and uric acid concentrations, reflecting a decrease
in liver ATP. After fructose administration there was a tem-
porary decrease in liver T4 uptake that normalized after
fructose was metabolized and hepatic ATP concentrations
were restored, as reflected by the normalization of serum
lactic acid and uric acid levels (134). In contrast to the tran-
sient effect of fructose, transport of T4 into the liver remained
suppressed when the same subjects were studied on a cal-
orie-restricted diet (Fig. 4). As will be discussed in Section
VII.C, NEFAs that circulate in increased concentrations dur-
ing caloric restriction have an additional inhibitory effect on
T4 uptake by the liver.
We also studied renal handling of T4 and T3 in humans
during fasting (174). The results suggested inhibition of T4
and T3 uptake at the basolateral membrane of the tubular
cells in the kidney. As to the cause of this inhibition, several
factors were proposed, including a decreased energy state of
the cells, the existing acidosis, and/or inhibition of transport
by the increased serum NEFA concentration.
C. In nonthyroidal illness
NTI may be defined as any acute or chronic illness, not
related to the thyroid gland, that is accompanied by an ab-
normal pattern of thyroid function parameters. Other terms
that are synonymously being used are the “low T3 syn-
drome” because serum T3 is invariably low in NTI, and the
“euthyroid sick syndrome” because patients are usually clin-
ically euthyroid despite the low serum T3 and sometimes also
FIG. 4. Computed kinetics of T4 uptake into the rapid equilibrating
pool (REP, representing largely liver) in four obese volunteers, before
(Œ) and during (F) caloric deprivation and after intravenous fructose
(f). [Derived from Refs. 134 and 170.]
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low T4 levels. With an increase in severity of disease there is
a progressive decrease in serum T3 and, in most diseases, an
increase in serum rT3 that eventually plateaus. Serum T4 is
usually normal but may be slightly increased in mild disease
and lowered in critical illness (Fig. 5). Serum TSH is usually
normal but may be depressed in severe illness (175, 176).
Many studies of thyroid hormone distribution and turnover
kinetics in patients with NTI have been reported (for reviews
see Refs. 171,175–177). In general, they show that T4 pro-
duction rates are normal, except in severe illness when it is
decreased, but that T4 transport into tissues is decreased.
Plasma rT3 production, virtually all originating in type III
deiodinase-containing tissues, such as brain (177), is normal
in NTI, while the plasma rT3 clearance, almost exclusively by
the liver (178), is decreased. Plasma T3 production rates are
invariably decreased in proportion to the severity of disease,
while plasma T3 clearance is generally little affected (175).
Few studies, mostly by Kaptein et al. (179–183), reported on
the analysis of unidirectional T4 transport into tissues during
NTI to determine its possible contribution to low plasma T3
production. Thus, in a group of 11 patients with acute critical
illness, T4 transport into tissues was inhibited by 50% and
T3 plasma production decreased by70%. From this analysis
it is not known to what extent inhibition of T4 transport
occurs in T3-producing tissues, predominantly the liver (see
Section VII.A). In another study in 15 patients with NTI due
to various causes (180), these authors found an inhibition of
T4 transport into the rapidly equilibrating pool (representing
liver and kidneys) by30% and into the slowly equilibrating
pool (representing the remaining tissues) by 65%. Plasma
T3 production rates were not reported in this study. In pa-
tients with chronic renal failure, tissue transport of T4 was
inhibited by 50%, but no data were presented for T3 pro-
duction (181). In contrast to most patients with NTI, who
show normal plasma rT3 production but decreased plasma
rT3 clearance (see Section VII.A) and thus elevated rT3 plasma
concentrations, this and other studies (for review see Refs.
182 and 183) demonstrate that patients with CRF have nor-
mal plasma rT3 levels, clearance rates, and production rates.
The fact that plasma T4 clearance is much more affected than
that of T3 is in agreement with similar findings in fasting
humans (see Section VII.B), and suggests that hepatic ATP
depletion may also be important here, which does not seem
illogical since NTI patients are mostly, if not always, in a
negative energy balance.
We also considered the possibility of circulating inhibitors
of thyroid hormone uptake in NTI. In the presence of serum
from patients with severe NTI, T4 uptake by rat hepatocytes
was50% lower than in the presence of serum from healthy
controls, without any direct effect on the deiodination pro-
cess (184). Further characterization of the factors responsible
for this inhibition identified several compounds circulating
at increased serum concentrations in patients with NTI, in-
cluding CMPF and indoxyl sulfate in patients with renal
failure (108), and bilirubin and NEFAs in nonuremic criti-
cally ill patients (109). It also appeared that in mild NTI and
during caloric restriction in obese subjects, serum NEFAs are
increased to levels that inhibit hepatocyte uptake of T4 (110).
Remarkably, T4 uptake in the rat pituitary is not inhibited by
concentrations of CMPF, indoxyl sulfate, and bilirubin that
inhibit T4 uptake in hepatocytes (185, 186). In addition, T3 and
T4 uptake was normal in rat pituitary cells with low ATP
concentration due to culture in an energy-poor medium.
These phenomena indicate different effects of pathophysio-
logical factors on the common pituitary transporter for both
T4 and T3 (Table 3, Refs. 68–70) compared with the specific
T4 transporter in the liver. We hypothesized that this differ-
ential transport handling may serve to maintain low T3 pro-
duction in starvation and NTI, by allowing T3, T4, and the
bioactive metabolites triiodothyroacetic acid and 3,5-diiodo-
thyronine (187, 188), which circulate at increased levels in
NTI (189, 190), and possibly also 3,3,5,5-tetrathyroacetic
acid (191, 192), to enter the pituitary to prevent any com-
pensatory increase in TSH (193). As a low T3 level is asso-
FIG. 5. Schematic representation of
the changes in serum thyroid hormone
levels in patients with nonthyroidal dis-
orders relative to the severity of the ill-
ness. [Reproduced with permission
from E. M. Kaptein. In: Thyroid hor-
mone metabolism. New York: Marcel
Dekker, 1986 (175).]
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ciated with conservation of energy and possibly also protein,
it is considered by some as a defense mechanism in situations
of stress. This point, however, is controversial as conflicting
results have been obtained in studies of this protein-sparing
effect. For further orientation about this subject, the reader is
referred to Ref. 171.
In summary, most plasma T3 is produced by conversion of
T4 in peripheral tissues, in particular the liver. Nuclear re-
ceptor-bound T3 in different tissues is derived to varying
extents from plasma T3 or from local deiodination of T4.
Thus, the exertion of the biological activity of thyroid hor-
mone requires the transport of T4 and T3 across the plasma
membrane. Analyses of thyroid hormone kinetics in humans
during caloric restriction revealed a 50% inhibition of hepatic
T4 transport, roughly equal to the 40% decrease in plasma T3
production, whereas the T4-to-T3 conversion in the liver was
not affected. These findings suggest a rate-limiting role of
hepatic T4 transport for plasma T3 production. The inhibition
of T4 transport was ascribed to hepatic ATP depletion by
fasting. Liver ATP depletion by fructose infusion in humans
indeed leads to a concomitant decrease of hepatic T4 trans-
port. In nonthyroidal illness, apart from a decrease of liver
ATP, increased plasma concentrations of compounds such as
CMPF, indoxyl sulfate, bilirubin, and NEFAs may inhibit T4
transport into the human liver, thereby contributing to the
low plasma T3 production in this condition. NEFA concen-
trations are also elevated in starvation and may thus con-
tribute to decreased hepatic T4 uptake and T3 production
during caloric deprivation.
VIII. Requirements for a Regulatory Role of Plasma
Membrane Transport in the Bioavailability of
Thyroid Hormone
Although it has been amply discussed in the previous
sections that in most, if not all, cells thyroid hormones cross
the plasma membrane by a carrier-mediated (often energy-
dependent) mechanism, its significance for the regulation of
the bioavailability of thyroid hormone has not yet been ad-
dressed. This will be done in the following sections.
Certain requirements must be fulfilled before it can be
concluded that the process of transport across the plasma
membrane of target cells is potentially regulatory for the
bioavailability of thyroid hormone and thus may have a role
in the regulation of thyroid hormone bioactivity. These re-
quirements are depicted in Table 5 and are discussed below.
A. Specificity of plasma membrane transport
Specificity of transport indicates that only structurally re-
lated substances are being transported or compete with the
transport system. These systems are saturable and usually
have limited capacity. Specificity of thyroid hormone trans-
port into target cells has been substantiated for many cell
types from many species as discussed in the different sec-
tions above. In some, but not all, cell types two systems have
been detected for uptake of iodothyronines (Tables 1–3). If
two systems were identified, the high-Km site was attributed
to binding of thyroid hormone to protein trapped in the
water layer around the cell or associated with the cell surface
(45). There is little doubt that in most cell types stereospecific
transport of thyroid hormone across the plasma membrane
occurs. The reported Km values of transport varied but were
mostly in the nanomolar range (Tables 2 and 3). The use of
different conditions and techniques as well as the tissue-
specific distribution of different transporters (see Section IX)
may account for this variation. A point of apparent discrep-
ancy is the fact that some laboratories could not identify a
specific T4 transport system whereas others could. This fact
is probably related to the phenomenon that T4 transport into
cells, at least into the hepatocyte, is much more sensitive to
suboptimal cellular ATP concentrations than T3 transport
(Ref. 48, Section III.B.2, and Fig. 1). When studies of T4 trans-
port are not focused on this aspect (92, 93), T4 transport may
become undetectable.
B. Absence of significant diffusion
If a significant proportion of thyroid hormone transport
across the plasma membrane would take place by diffusion,
it is obvious that this would diminish the role of the plasma
membrane in the regulation of hormone uptake. There is
substantial evidence, on both theoretical and experimental
grounds, that little or no diffusion occurs in the transport
process. Thus, although overall iodothyronines are lipophilic
compounds, the highly polar zwitter-ionic nature of the ala-
nine side chain prevents passage of the molecule through the
hydrophobic inner core of the lipid bilayer of the plasma
membrane. Experimental evidence has also been provided
that diffusion hardly takes place if at all. Thus, using an
electron spin resonance stop-flow technique, it was shown
that a spin-label derivative of T3 does not flip-flop at any
appreciable rate in phospholipid bilayers and that, after par-
titioning into the membrane, it remains in the outer half of
the bilayer (194). In other words, if no specific transport sites
were present in the membrane of target cells, thyroid hor-
mones would not be able to cross the plasma membrane.
Using a monoclonal antibody raised against a rat hepatocyte
surface epitope involved in thyroid hormone transport, a
concentration-dependent inhibition of the transport of T3
and T4 was observed, with 100% inhibition at a low (1:100)
antiserum dilution (40). The same monoclonal antibody also
strongly inhibited uptake of T4, T3, and rT3 in cultured hu-
man hepatocytes (52). In rat anterior pituitary cells and also
in Xenopus laevis oocytes, minimal, if any, uptake of T3 sulfate
(T3S) was detected, in contrast to specific uptake of T4 and T3
in these cell types (195, 196). However, injection of rat liver
mRNA induced uptake of T3S in these oocytes (Ref. 197 and
Fig. 6). These observations indicate that diffusion plays no
role in transmembrane transport of sulfated iodothyronines.
TABLE 5. Characteristics of plasma membrane transport of thyroid
hormone required for its potential function in the regulation of
thyroid hormone bioavailability
1. Specificity of plasma membrane transport
2. Absence of significant diffusion
3. Plasma membrane transport is subject to regulation
4. Transport is rate-limiting for subsequent metabolism
464 Endocrine Reviews, August 2001, 22(4):451–476 Hennemann et al. • Plasma Membrane Transport of Thyroid Hormones
 at Medical Library Erasmus MC on November 21, 2006 edrv.endojournals.orgDownloaded from 
C. Plasma membrane transport is subject to regulation
As the serum concentrations of free T3 and free T4 are in
the picomolar range, whereas their apparent Km values for
the plasma membrane transporters are in the nanomolar
range, no regulation of transport occurs by the process of
saturation. However, as pointed out above (see Sections III,
V, and VII) thyroid hormone transport into cells, except
maybe for erythrocytes, is dependent on the energy state of
the cell and often on the Na gradient over the plasma
membrane. Thus, cellular ATP and the Na gradient may be
important factors in the regulation of the activity of thyroid
hormone transporters (Tables 2 and 3), while thyroid hor-
mone uptake will also depend on the number of transporters
located in the cell membrane. The latter is determined not
only by the balance between the rates of synthesis and deg-
radation of these proteins but also by mechanisms regulating
their translocation between intracellular organelles and the
plasma membrane. Circulating inhibitors such as CMPF, in-
doxyl sulfate, bilirubin, NEFAs, and amino acids (Refs. 108–
110 and Section III.C.1) are also involved in the regulation of
thyroid hormone uptake, especially in starvation and non-
thyroidal illness. However, in tissues in which thyroid hor-
mone is taken up by amino acid transporters that mediate
exchange between extra- and intracellular ligands, hormone
uptake is subject not only to cis-inhibition by extracellular
amino acids but also to trans-stimulation by intracellular
amino acids.
The possible effects of thyroid state on the rate of thyroid
hormone uptake has been studied in rat liver. When livers of
hypothyroid rats were perfused, uptake of T3 was not dif-
ferent from normal, but T3 metabolism was decreased. In
livers of hyperthyroid rats, uptake of T3 was decreased and
T3 metabolism was increased. These data suggest an adap-
tation mechanism at the cellular level to maintain tissue T3
levels when T3 supply is abnormal (198). When expression of
mRNA of thyroid hormone transporters in rat liver was
studied, using Xenopus laevis oocytes as the expression sys-
tem, no thyroid state-dependent differences were seen in the
expression of these transporters, not excluding, however,
any regulation of transporter activity at the translational or
posttranslational level (199).
Thus, although questions remain, a number of factors,
both intracellular and circulating, have been identified that
determine the amount of thyroid hormone taken up by target
cells.
D. Transport is rate limiting for subsequent metabolism
Plasma membrane transport is rate limiting for cellular
thyroid hormone metabolism if any change in transport re-
sults in proportional alterations in subsequent metabolism.
This implies that influx of thyroid hormones is independent
of intracellular metabolic capacity. When rat hepatocytes in
primary culture were incubated with T4, T3, or rT3 in the
presence of an iodothyronine transport-blocking monoclonal
antibody or ouabain to lower the Na gradient over the
plasma membrane, a decreased clearance from the medium
of these iodothyronines was found that paralleled a de-
creased iodide production (Table 6). As it was shown that the
added compounds had no effect on intracellular deiodinase
activity, it was concluded that the decreased iodide produc-
tion was caused by the inhibition of iodothyronine uptake
(50). In addition it was reported from different laboratories
that compounds that inhibit T3 uptake at the plasma mem-
brane level, and do not influence nuclear binding of T3 per se,
effected a decrease in nuclear occupancy that paralleled the
inhibition of uptake, indicating that cellular uptake controls
T3 access to its receptors (77, 122, 200). These findings were
obtained using rat pituitary tumor cells, hepatocytes, and
skeletal myoblasts. Furthermore, uptake of T3S induced in X.
laevis oocytes by injection of fractionated rat liver mRNA was
not affected by coinjection with cRNA coding for type I
deiodinase. Thus, an increase in the capacity of oocytes to
FIG. 6. Initial uptake of T3S in X. laevis oocytes injected with water
(control), fractionated rat liver mRNA, cRNA for rat liver type 1
deiodinase (G21), or both (G21  mRNA). Values are means  SEM;
*, P  0.001 vs. water. [Modified reproduction with permission from
R. Docter et al.: Endocrinology 138:1841–1846, 1997 (197). © The
Endocrine Society.]
TABLE 6. Remaining iodothyronine and iodide released in medium
after incubation of rat hepatocytes in monolayer culture with T4,
T3, or rT3 in the absence (control) or presence of uptake inhibitors
ER-22 (monoclonal antibody) and ouabain
Percentage (mean  SEM)
Iodothyronine Iodide
T4
Control 82.9  0.8 12.7  0.4
ER-22 90.7  1.2a 6.9  0.6a
Ouabain 92.2  1.2a 7.0  0.6a
T3
Control 32.0  1.4 51.5  0.6
ER-22 64.8  1.4a 24.6  0.6a
Ouabain 66.2  1.4a 21.5  0.6a
rT3
Control 45.8  0.9 54.1  0.5
ER-22 62.8  1.1a 36.9  0.7a
Ouabain 56.8  1.6a 41.0  0.9a
a Significantly different from control, P 0.001. [Reproduced with
permission from G. Hennemann et al.: Endocrinology 119:1870–1872,
1986 (50). © The Endocrine Society.]
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metabolize T3S did not affect T3S uptake (Fig. 6 and Ref. 197).
Obviously, the rate of T3S metabolism was stimulated by
both induction of T3S transport and induction of deiodinase
activity. A remarkable finding was reported by our labora-
tory in support of the clinical relevance of inhibited hepatic
T4 transport as a cause for a decrease in T3 production (58,
201). When rat hepatocytes in primary culture were incu-
bated with T4 in the presence of serum from patients with
NTI, a strong correlation (r  0.69) was observed between
residual transport of T4 into the hepatocytes and the serum
T3 concentration in these subjects (Fig. 7). In other words, the
more inhibition of T4 transport exerted by the serum, the
lower the serum T3 concentration of that particular patient.
There is evidence that in vivo inhibition of T4 transport into
the liver is also rate-limiting for total plasma T3 production
in humans. In a female in her 60s, an increased serum free T4
concentration was present in combination with a low plasma
T3 concentration in the absence of NTI or any abnormality of
serum thyroid hormone-binding proteins (202). Iodothyro-
nine kinetic studies revealed that T4 uptake (and content) in
the rapidly equilibrating compartment, comprising mainly
the liver (and kidneys), was inhibited, but uptake in the
slowly equilibrating compartment, consisting of the other
tissues, was normal (Fig. 8). T3 uptake was normal in both
compartments. Plasma T3 production was subnormal, but
the ratio of T3 production over hepatic T4 uptake or T4 con-
tent was normal. It was concluded from these data that the
lowered plasma T3 production was caused by inhibition of
T4 uptake into the liver, leading to a decrease in substrate
available for conversion to T3, whereas the liver capacity to
produce and secrete T3 was unimpaired (202). We have iden-
tified this abnormal serum thyroid hormone profile also in
another subject (203). In this latter subject, serum TBG was
elevated and normalized upon administration of physiolog-
ical amounts of T3. As TBG may be elevated in hypothy-
roidism, this suggests that the lowered T3 production caused
hypothyroidism at the level of the liver. These human studies
suggest that inhibition of T4 transport into the liver, leading
to lowered T3 production, has biological consequences.
In summary, to play an important role in the regulation of
tissue thyroid hormone bioavailability, the mechanism of
transport of thyroid hormone over the plasma membrane
must fulfill certain requirements (Table 5). Thus, plasma
membrane transport should be specific, subject to regulation,
and rate limiting for subsequent thyroid hormone metabo-
lism. This implies that there is only limited or no diffusion
into target cells such that influx of hormone is largely effected
by specific transporters. Collectively, the studies discussed in
this section have demonstrated that this is indeed the case in
liver and many other tissues. Hepatic uptake of thyroid hor-
mone is regulated by the energy charge of the cells, and also
by compounds that circulate at increased levels in humans
during starvation (NEFAs) and nonthyroidal illness (NEFAs,
CMPF, indoxyl sulfate, and bilirubin). The reduced T4 trans-
port into the liver is a major cause for the decreased plasma
T3 production in these conditions.
IX. Identification of Thyroid Hormone Transporters
A. Organic anion transporters
Recently, we have explored the possibility to clone iodo-
thyronine transporters from rat liver using X. laevis oocytes
as an expression system (197, 204–207). A modest increase in
T4 and T3 uptake was induced by injection of oocytes with
rat liver mRNA, in particular the 0.8–2.1 kb size fraction,
above the background iodothyronine uptake by native oo-
cytes (197). Much lower background uptake was observed
with the sulfonated iodothyronine derivatives, T3 sulfate
(T3S), T4 sulfate (T4S), T3 sulfamate (T3NS), and T4 sulfamate
(T4NS), resulting in much larger relative inductions by in-
jection with rat liver mRNA (197, 204). Uptake of these water-
soluble derivatives was competitively inhibited by T4 and T3,
suggesting that they are alternative ligands for the iodothy-
ronine transporters (197, 204). Since the sulfonated com-
pounds are organic anions, we tested the hypothesis that
hepatic uptake of iodothyronine derivatives is mediated, at
least in part, by organic anion transporters, in particular
FIG. 7. Relationship between iodide
production from T4 (corrected for differ-
ences in free hormone concentration) in
the presence of 10% NTI serum, ex-
pressed as percentage of iodide produc-
tion in the presence of 10% serum of
healthy controls and serum T3. [Repro-
duced with permission from R. A. Vos et
al.: J Clin Endocrinol Metab 80:2364–
2370, 1995 (58). © The Endocrine
Society.]
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Na/taurocholate-cotransporting polypeptide (NTCP) and
the (Na-independent) organic anion transporting polypep-
tides (OATPs) (208, 209).
Human and rat NTCP are 349- to 362-amino acid proteins
containing seven putative transmembrane domains and two
glycosylation sites with an apparent molecular mass of 50
kDa (208–211). This transporter is now also known as solute
carrier family 10, member 1 (SLC10A1). NTCP is only ex-
pressed in hepatocytes, where it is localized selectively to the
basolateral cell membrane (208, 209). It is the major trans-
porter of conjugated bile acids in liver, but it also mediates
uptake of unconjugated bile acids and a number of non-bile
acid amphipathic compounds, including estrogen conjugates
such as estrone 3-sulfate (208, 209). A homologous bile acid
transporter is expressed in ileum and kidney, where it is
localized to the apical cell membrane (212–215). The OATPs
constitute a large family of homologous Na-independent
transporters, which are now comprised in the solute carrier
family 21 (SLC21). Seven members of this family have been
identified in rats, i.e., rOATP1–5 (216–221), rOAT-K1 (222),
and splice variant rOAT-K2 (222, 223), and the PG trans-
porter rPGT (224); eight members in humans, i.e., hOATP-A
to -F (225–230), hOATP8 (231), and hPGT (232); and two
members in mice, i.e., mOATP1 (233, 234) and mPGT (235).
rOATP1 was the first identified member of this transporter
family, representing a 670-amino acid protein with 12 trans-
membrane domains and 2 glycosylation sites with an ap-
parent molecular mass of 80 kDa (208, 209). The other OATP
transporters have similar structures. The tissue distribution
of the OATPs varies among the different members, e.g.,
rOATP1 and rOATP2 are expressed in liver, kidney, and
brain, rOATP4 and hOATP-C (alias hLST-1, liver-specific
transporter) are expressed exclusively in liver, and rOAT-K1
and -K2 are expressed selectively in kidney. Like NTCP, the
FIG. 8. T4 uptake into the rapidly
equilibrating pool (REP, upper panel)
and the slowly equilibrating pool (SEP,
lower panel) of a subject with reduced
peripheral T3 production (E) and con-
trol subjects (Œ) during the first 400 min
of T4 tracer kinetics. Values are the
mean SEM. [Reproduced with permis-
sion from G. Hennemann et al.: J Clin
Endocrinol Metab 77:1431–1435, 1993
(202). © The Endocrine Society.]
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OATPs expressed in liver are localized to the basolateral cell
membrane. It is interesting to note that in brain both rOATP1
and rOATP2 show prominent localization in the choroid
plexus, which may be an important gate of thyroid hormone
to the brain (209). The OATPs are multispecific transporters,
mediating the uptake of a wide variety of amphipathic li-
gands, not only anionic (e.g., conjugated and unconjugated
bile acids, conjugated steroids, bromosulfophthalein), but
also neutral (e.g., steroids, cardiac glycosides), and even cat-
ionic (e.g., ajmalinium) compounds (208, 209). For different
OATPs, it has been demonstrated that they facilitate the
exchange of intra- and extracellular anions (236, 237). Intra-
cellular reduced glutathione (GSH) is an important intracel-
lular ligand, the efflux of which down its large electrochem-
ical gradient provides the driving force for uptake of
extracellular ligands (236). Figure 9 shows the phylogenetic
tree of the OATP transporter family.
We observed marked stimulation of the uptake of native
iodothyronines as well as their sulfamate and sulfate deriv-
atives after injection of oocytes with cRNA for rNTCP,
hNTCP, rOATP1, rOATP2, or hOATP-A (206, 207). The Na
dependence of the NTCPs and the Na independence of the
OATPs were confirmed with all these ligands. Significant
transport of T4 and T3 has also been reported by others for
rOATP2 (218), rOATP3 (218), and rOATP4 (219), but not its
splice variant rLST-1 (220), for hOATP-C, alias hLST-1 (227,
228), and human and rat hOATP-E (238). The degree of
stimulation of iodothyronine uptake varied among the dif-
ferent OATP family members, e.g., rOATP1 showed highest
iodothyronine transport with T4 and rT3, and hOATP-A with
T3 as ligand (207). Apparent Km values were determined for
T4 and T3 transport by rOATP2, rOATP3, and hOATP-C, and
found to be in the micromolar range (218, 227). Together,
these data suggest that tissue uptake of thyroid hormone
may be mediated in part by different Na-dependent and
Na-independent organic anion transporters, although the
NTCPs and OATPs do not represent the high-affinity iodo-
thyronine transporters detected in different tissues. Studies
of the induction of iodothyronine transport by injection of
Xenopus oocytes with liver mRNA size fractions have indi-
cated the existence of a major Na-dependent transporter in
addition to rNTCP and rOATP1 (204, 207).
B. Amino acid transporters
A large number of amino acid transporters has been char-
acterized in recent years, including the 4F2-related het-
erodimeric transporters (239, 240). The 4F2 or CD98 cell sur-
face antigen is expressed in many tissues, especially on
activated lymphocytes and tumor cells, and has recently been
identified as a family of amino acid transporters (239, 240).
These transporters are now comprised in the solute carrier
family 7 (SLC7). These heterodimeric transporters consist of
a common 4F2 heavy chain (4F2hc) linked through a disul-
fide bond to one member of a family of homologous light
chains, seven of which have now been cloned (239–262).
4F2hc is a glycosylated protein with a single transmembrane
domain, whereas the light chains are not glycosylated and
have 12 transmembrane domains (239, 240). However, most
investigators agree that one of the light chains (b0,AT)
dimerizes preferentially with rBAT (for “related to basic
amino acid transport”), another heavy chain homologous to
4F2hc (256–259). Cystine is an important ligand for the
rBAT/b0,AT transporter (Table 7), and mutations in the
rBAT heavy chain have been identified in patients with type
I cystinuria (263), while mutations in the b0,AT light chain
have been found in patients with non-type I cystinuria (256–
258). The characteristics of the different heterodimeric amino
acid transporters are summarized in Table 7. The several 4F2
and rBAT-related heterodimeric transporters facilitate ex-
change of extra- and intracellular amino acids (239, 240).
We have studied possible transport of iodothyronines (T4,
T3, rT3, and 3,3-T2) by four heterodimeric amino acid trans-
porters, consisting of h4F2hc and either hLAT1, mLAT2,
hyLAT1, or hyLAT2 in Xenopus oocytes (264). The LAT1
and LAT2-containing heterodimers represent isoforms of the
system L amino acid transporters, which mediate the Na-
independent uptake of neutral amino acids. The 4F2hc/
LAT1 transporter shows preference for large neutral
(branched chain and aromatic) amino acids such as Leu, Tyr,
Trp, and Phe, whereas 4F2hc/LAT2 also transports small
neutral amino acids such as Gly, Ala, Ser, and Thr (241–250).
The heterodimers containing the yLAT1 or yLAT2 light
chains mediate the Na-dependent transport of neutral
amino acids such as Leu as well as the Na-independent
transport of basic amino acids such as Arg, which is char-
acteristic of the system yL amino acid transporters
(251–255).
Iodothyronine uptake in Xenopus oocytes was not affected
FIG. 9. Phylogenetic tree of the family of human, rat, and mouse
OATP organic anion transporters, based on the alignment of the
amino acid sequences using the ClustalW program (http://www.ebi.
ac.uk),andconstructedusingtheTreeViewprogram(http://taxonomy.-
zoology.gla.ac.uk/rod/treeview.html). Boxed transporters have been
shown to transport iodothyronines.
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by coexpression of 4F2hc and either yLAT1 or yLAT2,
although the Na-dependent transport of Leu, Phe, and Tyr
and the Na-independent uptake of Arg were markedly
increased (264). This indicates that thyroid hormone trans-
port is not mediated by 4F2-related, system yL amino acid
transporters. However, coinjection of oocytes with cRNA for
both 4F2hc and LAT1, but not for each subunit alone, re-
sulted in marked increases in (Na-independent) uptake of
the system L ligands Leu, Phe, Tyr, and Trp, and of the different
iodothyronines. At subsaturating ligand concentrations, the
rate of iodothyronine uptake by the h4F2hc/hLAT1 transporter
decreased in the order 3,3-T2T3rT3T4. Apparent Km val-
ues were found to be in the micromolar range, being lowest for
T3 (0.8 m), which is the lowest value reported for a ligand
of the h4F2hc/hLAT1 transporter (241–245). Both apparent
Km (8 m) and Vmax values were highest for 3,3-T2 (264).
Significant but smaller increases in uptake of the different
iodothyronines were observed in oocytes coexpressing 4F2hc
and LAT2 (264). In addition, Ritchie et al. (265) have reported
on the stimulation of T3 transport in oocytes injected with
cRNA for 4F2hc and for the IU12 Xenopus LAT1 homolog.
These results, therefore, strongly confirm previous findings
suggesting that thyroid hormone uptake in different cell
systems is mediated by L type amino acid transporters (see
Section III.C). However, the T type amino acid transporter
thought to be involved in the uptake of thyroid hormone in
erythrocytes (94) has yet to be characterized.
In contrast to the ubiquitous expression of the 4F2 heavy
chain, the LAT1 and, in particular, LAT2 light chains show
restricted tissue distributions (239–250). This suggests the
existence of additional light chains involved in the uptake of
aromatic amino acids and iodothyronines in tissues that do
not express LAT1 or LAT2, one of which may be the subunit
for the system T transporter. It has not been tested whether
iodothyronines are transported by the rBAT/b0,AT het-
erodimeric transporter. Perhaps, other light chains combine
with rBAT and mediate transport of iodothyronines. Iodo-
thyronines may also be ligands for completely different
classes of neutral (aromatic) amino acid transporters, such as
the recently cloned Na-dependent B0, transporter (266).
In summary, recent studies have identified plasma mem-
brane transporters that are capable of mediating cellular
uptake of thyroid hormone. These include 1) the rat and
human Na-dependent organic anion transporter (NTCP),
which is expressed exclusively in the basolateral liver cell
membrane, 2) different members of the rat and human Na-
independent organic anion transporter (OATP) families,
which show different tissue distributions, and 3) the L type
heterodimeric amino acid transporters, comprised of the hu-
man 4F2 heavy chain and the LAT1 or LAT2 light chains,
which are expressed in different, largely extrahepatic tissues.
The physiological relevance of these transporters for tissue
thyroid hormone uptake, however, remains to be established.
X. Summary and Conclusions
There is little doubt that thyroid hormones and their an-
alogs are transported into target cells via plasma membrane
carriers. Although variations exist in reported Km values,
explained in part by differences in laboratory techniques and
conditions, but also by different tissue distribution of the
various transporters, it seems that the mechanism of satu-
ration does not play a role in the regulation of thyroid hor-
mone access to cells. Most laboratories report apparent Km
values in the nanomolar range (Tables 1–3) that are 3 orders
of magnitude higher than serum free hormone concentra-
tions. However, other factors have been identified that are
involved in regulating thyroid hormone cellular uptake. Cel-
lular factors include the energy charge, in particular cellular
ATP concentrations, the number of carriers per cell, and the
Na gradient over the plasma membrane. Extracellular fac-
tors comprise the free hormone concentration, and possibly
competition by circulating amino acids. Several groups of
amino acids were shown to inhibit thyroid hormone trans-
port at physiological serum concentrations. Also substances
circulating in increased concentrations in NTI and starvation,
such as CMPF, indoxyl sulfate, bilirubin, and NEFAs, and
several drugs may influence thyroid hormone tissue uptake.
Strong evidence exists that plasma membrane transport of
thyroid hormone is rate limiting for subsequent thyroid hor-
mone metabolism. As in man about 80% of plasma T3 is
produced outside the thyroid gland from T4 in plasma T3-
producing tissues, regulation of uptake of T4 in these tissues
is potentially determinant for overall plasma T3 production
and thus exertion of thyroid hormone activity at the tissue
TABLE 7. Characteristics of heterodimeric amino acid transporters
Light chain Heavy chain Amino acids transported Localization Ref.
LAT1 4F2hc Large neutral (Na-independent)
e.g., Leu, Phe, Tyr iodothyronines
e.g., Brain, spleen, testis, placenta,
stomach, skeletal muscle
241–245
LAT2 4F2hc Broad, neutral (Na-independent)
iodothyronines
e.g., Kidney, intestine, placenta,
brain, liver, skeletal muscle
246–250
yLAT1 4F2hc Basic (Na-independent), e.g., Arg,
Lys, and neutral (Na-dependent),
e.g., Leu
e.g., Kidney, intestine 251–254
yLAT2 4F2hc Basic (Na-independent), e.g., Arg,
Lys, and neutral (Na-dependent),
e.g., Leu
e.g., Brain, intestine, heart,
kidney, testis
252,254,255
b0,AT rBAT Broad, basic, and neutral (Na-
independent), e.g., Lys, Arg,
cystine, Leu
e.g., Kidney, intestine 256–259
xCT 4F2hc Cystine, Asp, Glu Macrophage, brain 260
Asc-1 4F2hc Small neutral amino acids, e.g., Gly,
Ala, Ser, Thr, Cys
e.g., Brain, placenta, kidney,
skeletal muscle, heart
261,262
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level. This process probably plays a major role in the lowered
T3 production in NTI and starvation in man, in contrast to the
situation in the rat, where a diminished T4 production plays
an important if not major role in the cause of the low T3
syndrome (267, 268). The contributions of plasma-derived T3
and of local T3 production from T4 differs between tissues.
Thus, not only regulation of T4 uptake but also of T3 uptake
at the level of the plasma membrane is important for overall
regulation of thyroid hormone bioactivity. Plasma mem-
brane carriers for thyroid hormone may be different in dif-
ferent organs. For instance, in the liver there are probably
different carriers for T3, T4, and rT3, whereas in the pituitary
only one transport mechanism has been identified for both
T3 and T4. Transport mechanisms may also differ in various
tissues and species with regard to Na dependence and
maybe other, as yet unidentified, factors. Few publications
deal with cellular efflux of thyroid hormone. When tested, T3
efflux is found to be a saturable process, albeit at supra-
physiological hormone levels. Efflux of thyroid hormone,
even if carrier mediated, seems to be independent of the
energy charge of the cell. This suggests that carrier-mediated
efflux of thyroid hormone does not play a major role in the
regulation of the cellular free hormone concentration.
A very recent development is the identification of different
thyroid hormone transporters belonging to different fami-
lies. This field is developing rapidly; nonetheless, informa-
tion in the following areas is insufficient: 1) how and to what
extent these transporters compete for thyroid hormone trans-
port; 2) how they are distributed over the different tissues;
and 3) in what way other ligands for these transporters
interact with thyroid hormone transport into tissues. Insuf-
ficient information is also available about the rank order of
physiological importance of the different transporters. Once
more, knowledge has been accumulated about this aspect,
but studies must be done on the regulation at the molecular
level of the activity of physiologically important thyroid
hormone transporters and the mechanisms by which they
regulate bioavailability of thyroid hormone.
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